Coherus Oncology: Five Readouts Or More Possible In 2026

Group 1 - Coherus Oncology (NASDAQ: CHRS) has shown significant revenue growth from its product Loqtorzi (toripalimab) in Q2 2025 compared to Q1 2025 [1] - The company is approaching important milestones related to its developmental pipeline [1]